Canada approves second generic Ozempic; ex-U.S. price erosion accelerates

What happened

Canada's health regulator approved Apotex's generic semaglutide, the second copycat version of Novo Nordisk's Ozempic authorized in the country. This is the latest example of ex-U.S. patent erosion, following India's March 2026 patent expiry where generics launched at ~80% lower prices. The approval directly validates the DeepValue report's thesis that international markets face accelerating price fragmentation as semaglutide exclusivity lapses. While Canada is a smaller market, the pattern reinforces that Novo's global pricing power is eroding faster than modeled. The news adds another headwind to the already pressured earnings outlook, with U.S. net pricing also declining amid competition and access programs.

Implication

The analyst should incorporate faster ex-U.S. net price declines into valuation models, likely lowering fair value estimates. However, volume growth from CMS pilots could partially offset. The thesis that Novo must rely on volume over price is reinforced; without it, earnings power will reset lower.

Thesis delta

The thesis shifts from 'pricing pressure is primarily a U.S. phenomenon' to 'pricing pressure is now a global, multi-front battle.' The Canada generic approval accelerates the timeline for ex-U.S. revenue erosion, making Novo's volume-dependence strategy even more critical. The DeepValue report's bear-case scenario becomes more probable as patent expiry in additional markets (e.g., China, Europe) looms.